Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations.

Kolberg, Hans-Christian; Demetriou, Georgia Savva; Hanes, Vladimir

Kolberg, Hans-Christian; Demetriou, Georgia Savva; Hanes, Vladimir.

Afiliação

Kolberg HC; Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center, Marienhospital Bottrop GmbH, Josef-Albers-Str. 70, 46236, Bottrop, Germany. hans-christian.kolberg@mhb-bottrop.de.
Demetriou GS; Department of Medical Oncology, University of Witwatersrand, Johannesburg, South Africa.
Hanes V; Biosimilars Business Unit, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.

Oncol Ther ; 9(1): 225-238, 2021 Jun.

Article em En | MEDLINE | ID: mdl-33428085

Palavras-chave

ABP 980; Biosimilar; Breast cancer; Gastric cancer; Gastroesophageal adenocarcinoma; Kanjinti; Reconstitution; Switching; Trastuzumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies Idioma: En Revista: Oncol Ther Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google